Acute kidney injury related to iodinated contrast significantly increases morbidity and mortality after angiography or angioplasty. According to registries, its prevalence can vary from 2% in low-risk population to up to 50% in high-risk subjects. Its risk factors include previous renal failure, diabetes, age, and the amount/type of contrast used. As a preventive measure, international…
TCT 2022 | Pulmonary Artery Denervation in Primary Pulmonary Hypertension
Primary Pulmonary Hypertension is behind multiple hospitalizations and pulmonary transplants. Even though its treatment has been advanced, many patients will not respond well. The PADN-CFDA randomized 128 patients, 63 received pulmonary denervation (PADN) and 65 went to the control group. Primary end point was 6-minute walk distance test at 6 months. The populations were similar,…
SYMPLICITY HTN-3 Trial. Evolution at 3 Years
The SYMPLICITY 3-year outcomes are out. Bear in mind this is the largest study we have had so far. It included 535 patients. 364 received renal denervation (RDN) and 171 went to the control group. At 36-month followup, 101 patients crossed over. The procedure was safe at 36 months, both for patients receiving it at…
TCT 2022 | RADIANCE II Pivotal Trial
Renal denervation has been developed to treat blood hypertension. Even though at present is still not common, with the development of new technology and improved technique, its results are promising. The RADIANCE II Pivotal included 224 patients. 150 received renal denervation with ultrasound (uRDN) and 74 went to the control group. Efficacy primary end point…
Gender Differences and 10-Year Prognosis in STEMI
Coronary artery disease in women usually develops 10 years later than in men, and some evidence suggests women have higher mortality, especially when it comes to ST elevation MI (STEMI). Registries have shown higher mortality both in hospital and at one year follow up. In part, this difference is observed because of the gap in…
RADIANCE-HTN SOLO: Control Durability of BP
In patients with hard-to-control high blood pressure (HBP), both non-pharmacological treatment and lifestyle changes have been useful to improve its control. Renal denevartion (RDN) was assessed as part of this complementary treatment, since some research has shown that this alternative decreases blood pressure (BP) values in different groups treated with either radiofrequency or ultrasound (uRDN).…
Clinical Results of IVUS-Guided Drug-Eluting Stent Implantation in Femoropopliteal Disease
Endovascular treatment of femoropopliteal lesions has become the first-line treatment due to the development of devices that decrease the restenosis rate. Recently, the IMPERIAL study showed greater patency at 1 year and greater freedom from clinically guided revascularization at 2 years in favor of the ELUVIA stent (paclitaxel-eluting fluoropolymer, FP-DES) compared with the ZILVER PTX…
SOLACI-SOCIME 2022 | Big Necks, (PEVAR IN HOSTILE NECK) – Dr. Juan Varela
Veja esta apresentação do Dr. Juan Varela (COL) durante o Congresso SOLACI-SOCIME 2022 realizado na Expo Santa Fé, CDMX nos dias 4, 5 e 6 de agosto de 2022. Tema: Big Necks, (PEVAR IN HOSTILE NECK Session), Aug 4, Peripheral Room – 16:00 – 17:00 hs.
SOLACI-SOCIME 2022 | Rol de los Dispositivos Fenestrados en Hipertensión Arterial Pulmonar, by Dr. Daniel Springmuller
Read the most outstanding articles from the second day of the SOLACI-SOCIME 2022 Congress. In this case, consult the presentation by Dr. Daniel Springmuller, entitled “Rol de los Dispositivos Fenestrados en Hipertensión Arterial Pulmonar”
SOLACI-SOCIME 2022 | Pulsta Valve implantation : How do I do it?, by Dr. Alejandro Peirone
Read the most outstanding articles from the second day of the SOLACI-SOCIME 2022 Congress. In this case, consult the presentation by Dr. Alejandro Peirone, entitled “Pulsta Valve implantation : How do I do it?”
SOLACI-SOCIME 2022 | Surgical Pulmonary Valve Replacement, by Dr. Jorge Cervantes Salazar
Read the most outstanding articles from the second day of the SOLACI-SOCIME 2022 Congress. In this case, consult the presentation by Dr. Jorge Cervantes Salazar, entitled “Surgical Pulmonary Valve Replacement”